Researchers reported a platinum‑based complex that becomes active under X‑ray exposure and enhances radiotherapy efficacy by mechanisms distinct from traditional radiosensitizers. Preclinical results show improved tumour control in hypoxic models and evidence of increased immune activation when combined with checkpoint blockade. The study frames the compound as a potential radiosensitizer that could extend radiotherapy benefit in radioresistant microenvironments; translational work and safety characterization are next steps.